Additional European Equity News

AstraZeneca (AZN LN) - Q4 (USD): Core EPS 2.12 (exp. 2.14), Revenue 15.5bln (exp. 15.46bln), guides initial FY26 revenue up by mid-to-high single digit and core EPS up by double-digit percentage. (AstraZeneca) 

Barclays (BARC LN) - Q4 (GBP) Revenue 7.08bln (prev. 6.96bln Y/Y), PBT 1.86bln (exp. 1.76bln), NII 3.73bln (exp. 3.76bln); announces share buyback of GBP 1bln with plan to return at least £10bn of capital to shareholders between 2024 and 2026, through dividends and share buybacks, with a continued preference for buybacks. (Barclays)

Bellway (BWY LN) - 6 months trading update (2026): Growth in total housing completions to 4,702 homes (2025 – 4.6k) at an average selling price of around GBP 322k (2025 – GBP 310k). The forward order book at 31 January 2026 comprised 4.4k homes (2025 – 4.7k), with a value of GBP 1.24bln (2025 – £1.31bln). The GBP 150mln share buyback launched on 14 October 2025 is progressing well, with 1.76mln shares purchased at a cost of around GBP 48mln during the period. (Bellway) 

BP (BP/ LN) - Q4 2025 (USD): Adj. EPS 0.10 (exp. 0.099), Adj. Net 1.5bln (exp. 1.53bln), Board has decided to suspend share buybacks; Net Debt 22.18bln (exp. 23.04bln); Dividend per share 8.32c (exp. 8.29c); Operating Cash Flow 7.6bln (exp. 7.4bln); Reduces capital expenditure for 2026 to lower end of guided range. (BP) 

BT (BT/A LN) - Co. announces new leaders for Openreach and BT International (BT)

Coca-Cola HBC (CCH LN) - FY 2025 (GBP): Net sales revenue 11.6bln (prev. 10.75bln Y/Y), Operating profit 1.31bln (prev. 1.19bln Y/Y), EPS 2.59 (prev. 2.25 Y/Y). (Coca Cola HBC)

GSK (GSK LN) - Co.’s RSV vaccine, Arexy, accepted for regulatory review in China for adults aged 60 years and older. (GSK) 

Pennon Group (PNN LN) - Co. confirms news CEO start data (Pennon Group)

STMicroelectronics (STM FP) - Co. introduces the first automotive microcontroller with AI for edge intelligence. (STM FP)

Thule (THULE SS) - Q4 (SEK): Sales 1.84bln (exp. 1.78bln). FY: Net Sales 10.42bln (prev. 9.54bln Y/Y), EPS 10.33 (prev. 10.59 Y/Y). Proposes a dividend of SEK 8.30/shr (prev. SEK 8.30 Y/Y). (Thule) 

BASF (BAS GY) reiterates with Buy at Goldman Sachs 

Croda International (CRDA LN) reiterates with Sell at Goldman Sachs 

Novonesis (NSISB DC) reiterates with Buy at Goldman Sachs